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Abstract
Background: An effective drug to treat cryptosporidial diarrhea in HIV-infected individuals is a global health
priority. Promising drugs need to be evaluated in endemic areas which may be challenged by both lack of
resources and experience to conduct International Committee of Harmonisation-Good Clinical Practice (ICH-GCP)-
compliant clinical trials.
Methods: We present the challenges and lessons learned in implementing a phase 2A, randomized, double-blind,
placebo-controlled trial of clofazimine, in treatment of cryptosporidiosis among HIV-infected adults at a single site
in Malawi.
Results: Primary challenges are grouped under study initiation, study population, study implementation, and
cultural issues. The lessons learned primarily deal with regulatory system and operational barriers, and
recommendations can be applied to other human experimental trials in low- and middle-income countries,
specifically in sub-Saharan Africa.
Conclusion: This study demonstrated that initiating and implementing human experimental trials in sub-Saharan
Africa can be challenging. However, solutions exist and successful execution requires careful planning, ongoing
evaluation, responsiveness to new developments, and oversight of all trial operations.
Keywords: Clinical trial, Developing country, Sub-Saharan Africa, Low-resource setting, Cryptosporidiosis, Diarrhea,
Clofazimine
Background
Clinical trials, particularly human experimental trials,
are critical to learning the safety and efficacy of drugs
and therefore to treating diseases [1, 2]. Trials are espe-
cially needed to address the high burden of disease in
low- and middle-income countries (LMICs), specifically
in sub-Saharan Africa. For as much as 50% of the global
burden of disease, mostly due to infections, reside in
sub-Saharan Africa [3].
Clinical trials testing drugs and vaccines that target
specific diseases afflicting people in sub-Saharan Africa
are logically best run in those countries. These trials can
benefit from local healthcare knowledge and are better
able to address context-specific questions that would
then lead to more effective interventions [4]. Clinical re-
search conducted in LMICs, particularly sub-Saharan
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Africa, build both research and health care capacity [4],
which has been shown to strengthen health systems, ex-
pand health programming, and provide an evidence base
for future health crises responses [5]. Major operational
benefits of conducting trials in sub-Saharan Africa in-
clude the ease of recruiting trial participants and the
availability of health workers with clinical research ex-
perience [4].
Despite these facts, only 20–30% of global clinical tri-
als are conducted in LMICs and less than 10% in sub-Sa-
haran Africa (Fig. 1) [1]. Several barriers to conducting
research in sub-Saharan Africa contribute to this situation.
These barriers include financial and human capacity, de-
lays in regulatory and ethical reviews, complex logistical
and financial systems, and competing demands [4].
In the developing world, Cryptosporidium infection
and the associated diarrheal disease (cryptosporidiosis) is
life-threatening in persons with HIV infection and in
children younger than 5 years [7]. Currently, nitazoxa-
nide is the only licensed drug for the treatment of
cryptosporidiosis in immunocompetent persons after the
first year of life [8].
The first human experimental trial to evaluate the
therapeutic clofazimine (CFZ) for treatment of crypto-
sporidiosis was conducted in Malawi, a low-income
country with limited experience conducting clinical trials
and with even less experience conducting human
experimental trials. This study was classified as a phase
2a trial evaluating the safety, tolerability, pharmacokinet-
ics (PK), and efficacy of CFZ in cryptosporidiosis (Cryp-
tofaz). It was a two-part study (A and B) that took place
at Queen Elizabeth Central Hospital (QECH) in Blan-
tyre, Malawi [9]. Part A was a randomized, placebo-
controlled, double-blind clinical trial with a 1:1 ratio of
intervention to control. Part B was an open-label study,
comparing the PK of orally administered CFZ in HIV-
infected individuals with and without Cryptosporidium
diarrhea. Further details on the study protocol can be
found elsewhere [9]. Recruitment began in December
2017 and was completed in January 2019.
Similar to the experience of other clinical trials con-
ducted in sub-Saharan Africa, the Cryptofaz team encoun-
tered several logistical, operational, and implementation
challenges [9]. Addressing these challenges effectively was
key to conducting this clinical trial [10]. This article re-
ports on the lessons learned. These lessons can be useful
to other human experimental trials being considered or
conducted in sub-Saharan African settings.
Challenges
Topic areas are presented according to when they oc-
curred during the clinical study. The challenges, lessons
learned, and recommendations are listed in full in
Table 1.
Fig. 1 Distribution of clinical studies registered on ClinicalTrials.gov on April 2019 [6]
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Table 1 Main challenges, lessons learned, and recommendations




• Contracts and agreements between multiple
international institutions can cause delays.
• Obtaining ethics and regulatory approvals in Malawi is
a complex process that required significant time and
effort from study staff.
• Begin the process of getting partner agreements
even before the grant is approved.
• Confirm commitment of subcontractors during the
grant process.
• Ensure the site has dedicated in-country person ex-
perienced with the ethics and regulatory agencies
to focus on the processes and check outcomes. In
particular, they should:
° Facilitate study team’s finalization of protocols
and other documents to keep them in line with
submission dates.
° Check on progress immediately after review
deadline.
° Ensure that approval documents are received.
° Check returned documents for accuracy.
Trial insurance • Obtaining trial insurance in Malawi is complicated.
• The sponsor had to work through an institutionally
sanctioned insurance broker.
• The broker contracted with a multinational insurance
company who then contracted with a local insurance
firm in Malawi.
• Additionally, a local insurance firm then had to front
the policy before it could be endorsed by the
National Commission for Science and Technology
(NCST).
• Sponsor and study team should coordinate with
each other and with the various companies in
order to keep the process moving and ensure that
requirements are met.
Staffing • It takes planning, creativity, and tenacity to recruit and
retain excellent study personnel.
• Experienced personnel were generally already under a
contract either with a different MLW clinical trial or
other research institutions in the country.
• When promising clinicians (without specific clinical
trial experience) are hired, training, oversight,
mentorship, and timely feedback can ensure that staff
succeed.
• Plan hiring early.
• Contact investigators whose studies are ending.
• Whenever possible, draw from study teams that
have implemented similar studies.
• When promising staff are hired:
° Provide basic theoretical training on clinical
trials/clinical research.
° Provide specific hands-on training.
° Ensure ongoing support/supervision from





• Adequate information about the study population is
key.
• The number of potential subjects that would meet
inclusion criteria and fail due to exclusion criteria was
unknown, e.g., an exclusion criteria of potassium < 3.5
mEq/L was almost universal in this population with
prolonged diarrhea.
• Conduct pilot study specific to the planned trial in
order to gain a clear understanding of the realities.
• Focus especially on data that relates to inclusion
and exclusion criteria.
• For correctable inclusion criteria, such as potassium
levels, consider correction and a needed retesting
value.
Slow enrollment rate • Expected enrollment rate was based on a preliminary
study that did not match study requirements.
• Climate change is affecting weather patterns; this
impacts the prevalence of pathogens.
• Oral potassium supplements can address hypokalemia
within the recruitment time period, thus allowing
subject eligibility.
• Chest X-rays and sputum GeneXpert alone are not re-
liable in detecting TB; urine LAM identifies undiag-
nosed TB in immunocompromised HIV-infected
patients.
• Hospital-based recruitment was insufficient; expanding
to outreach sites led to an increase in the number of
potential subjects approached and subjects enrolled.
• Conduct pilot study in line with study parameters,
particularly related to study population.
• Verify the climate conditions that existed when
baseline data re: recruitment rate was gathered.
• Plan for changing weather patterns, i.e., conduct
the trial in multiple sites simultaneously.
• Be more conservative about estimates when
preliminary study inclusion/exclusion criteria do
not match study criteria.
• Identify strategies for dealing with slower than
expected enrollment.
• Consider setting study enrollment target off-ramps.
Study population health
status
• Potential participants were severely
immunocompromised and had multiple opportunistic
infections.
• Many were failing on ARV treatment.
• Related to above, many subjects were found to have
• Ensure consultation with expert clinicians.
• Consider ramifications of potential participants
failing first-line ARV treatment, thus eligible for sec-
ond-line treatments (identified in exclusion cri-
teria) rendering them ineligible.
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Table 1 Main challenges, lessons learned, and recommendations (Continued)
Challenge Lesson learned Recommendations
undiagnosed TB early in the study.
• Local clinical staff are able to ensure that subjects can
access available and appropriate treatment.
• Plan for extensive screening procedures (such as
urine LAM to rule out extrapulmonary TB) to
isolate exclusionary conditions.
• Facilitate referral for care and management.
• Provide clear instructions at discharge related to
worsening conditions and follow-up with subjects.
High mortality rate • Subjects with diarrhea, HIV, and Cryptosporidium had
CD4 counts uniformly under 100 and had multiple
underlying conditions that contributed to the
mortality rate.
• Mortality rate of 20% in part A was higher than the
anticipated rate of 15% (projected from published
data re: HIV+ individuals with diarrhea).
• Experienced HIV clinicians at the Data and Safety
Monitoring Board (DSMB) concluded that mortality
rate seen in this study was not unexpected.
• Before study begins, get input from experienced
in-country clinicians about expected mortality rates
for the specific population.
• Ensure that clinicians refer very ill subjects to
appropriate clinics to ensure proper care and
management.
Study implementation
Lab equipment • Identification of suppliers and acquisition of critical lab
equipment and supplies took more time than
anticipated.
• Maintenance of one malfunctioning piece of
equipment not easily obtainable in Malawi (in this
case, the Thermal Cycler, polymerase chain reaction
[PCR] machine) caused significant delays.
• Study team, including partners, should collaborate
to identify suppliers well ahead of trial initiation.
Establish realistic delivery timelines.
• Develop close communication with suppliers to
emphasize the critical importance of equipment to
the study to ensure equipment is delivered in a
timely manner and maintained.
• Maintain close contact with technical personnel
from suppliers to facilitate resolution of
malfunctioning equipment.
• Identify backup labs early to use when lab
machine is faulty, or reagents have run out.
Lab testing • Study required new skill sets for site staff, particularly
lab staff.
• Viability of ultra-cold cell specimens is not guaranteed.
• Clinical lab at site hospital did not run samples quickly
and not at night nor over weekends, causing
unanticipated delays.
• PK sample collection and other procedures spaced
too closely together can lead to errors.
• Enrollment rate of 2 subjects per week allowed
adequate time for processing of lab tests.
• Provide expert trainers to work with the site lab
personnel to establish new complicated
techniques and maintain feedback for ongoing
troubleshooting.
• Consider sending lab personnel to partner labs to
observe routine processes before initiating the trial.
• Develop a backup plan for cell culture including
backup shipments and alternative substrates.
• Ensure adequate and ongoing supply of reagents.
• Make arrangements to do clinical labs via study
labs or contract with the clinical lab to run the
samples immediately.
• Consider rolling admission days to ensure
adequate time for PK and other studies.
Randomization timing • Some procedures required study staff with regular
weekday hours to come in on holidays and weekends.
• Ensure that protocol is in line with work schedules
to ensure that adequate staffing is available.
Protocol amendments • Getting protocol amendments in place (and adjusting
related study documents) took more effort and time
than anticipated.
• Protocol revisions impact all downstream data entry
and document revisions.
• This can slow the progress of the study.
• Anticipate protocol amendments when conducting
studies in new areas.
• Plan for the impact of amendments and ensure
that study deadlines can be reached.
•Try to ensure quick consensus on proposed
protocol amendments by all concerned staff and
partners.
Data collection forms
(DCFs) and data entry
• DCFs contained unclear or incorrect fields.
• Missing data fields and data entry errors early in the
study caused numerous data queries.
• Significant staff time was required to correct the
forms and resolve the queries.
• Perform mock run-throughs of completing DCFs
and data entry with the clinical and data entry staff
at site initiation visit.
• Site data entry staff perform ongoing audits of
data fields before submitting.
• Ensure continuous and open communication
among the clinical, data entry, and CRO staff to
discuss queries and related data issues.
Physical space • Lack of space at QECH prevented separate clinic
rooms for subjects.
• Part B (non-diarrheic, non-Cryptosporidium-infected
individuals) needed separate inpatient space to
• Analyze space availability at study site against
study space needed (including office space).
• Ensure that adequate space is available to support
good health outcomes for both study participants
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Study initiation
Contracts and regulatory approvals
Agreements between key international institutions took
more time (several months when there was a need to ac-
complish this within several weeks) than anticipated.
Similar to the experience of other clinical trials being
conducted in developing countries, obtaining ethics and
regulatory approvals in Malawi required significant time
and effort from study staff [4].
Trial insurance
In order to get the required trial insurance in Malawi,
the sponsor and local site had to contract with four in-
surance companies. We were required to work through
an institutionally sanctioned insurance broker and this
created complications. The multiple layers of bureau-
cracy involved in getting the policy approved increased
the time to trial commencement.
Staffing
Hiring expert clinical trial personnel was a lengthy
process. Identifying seasoned candidates with clinical
trial experience is especially challenging in a less-
developed setting. Local populations generally have lim-
ited experience conducting clinical trials—though this is
increasing.
Study population
The study population involved HIV-infected adults with
three or more days of diarrhea who met all the inclusion
and none of the exclusion criteria [10].
Slow enrollment
Initial enrollment projections (66 subjects enrolled in 9
months) were based on a preliminary study previously
conducted in Blantyre, Malawi, where a rapid diagnostic
test was used on patients hospitalized with diarrhea over
a 3-month period to obtain rough estimates of the
prevalence of Cryptosporidium in the hospitalized popu-
lation (17%). The preliminary study captured informa-
tion on HIV status and clinical stage, diarrhea duration,
and age, but not information on the laboratory and clin-
ical exclusion criteria, such as electrolyte abnormalities
or tuberculosis testing. Unfortunately, the actual enroll-
ment rate for the Cryptofaz study (15 subjects in the first
10 months) did not match the projections.
There are several factors that accounted for the slow
enrollment. Initial recruitment was based on a diarrhea
duration of > 14 days, and it was difficult to find subjects
with this diarrhea duration who were also Cryptosporid-
ium positive by PCR. Therefore, the study team modified
the inclusion criteria in an effort to increase enrollment.
The required diarrhea duration was shortened as well as
the duration an individual could be on antiretroviral
Table 1 Main challenges, lessons learned, and recommendations (Continued)
Challenge Lesson learned Recommendations
prevent exposure to Cryptosporidium oocysts.
• If study had recruited the expected number of
subjects, trial participants could have taken beds
needed for non-study participants.
• QECH infrastructure had to be upgraded to create
office space for the clinical staff.
and non-study participants.
Site Internet connectivity • Internet connection is critical when an electronic data
system is used.
• When electronic systems are key to study
implementation, ensure the study site has a strong
Internet connection and identify backup plans,
several if possible.
• Consider cellular data as a way to ensure nearly
continuous connectivity.
Cultural issues
Blood draws • Superstition can cause subjects, their families, and
communities to object to study procedures.
• Uninformed ward staff can perpetuate misinformation
about study-related procedures.
• Staff awareness of community perceptions and
potential threats to the study is extremely useful to
prevent problems.
• Ensure strong links to District Health Offices.
• Suspend community recruitment during volatile
periods.
• Provide ongoing community, subject, and ward
staff education on the need for frequent blood
draws and the small amount of blood being taken.
• Ensure proper consenting with subjects and
guardians.




• Some subjects disliked the selected food supplement,
and one could not eat it.
• Mixing food supplement with instant maize porridge
(a common food staple) improved subjects’ ability to
consume it.
• Perform quick assessment before study initiation to
ensure the target population can consume
supplement.
• Adjust supplement, if needed, to make it more
suitable.
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therapy (ART). In addition, outreach was expanded to
include referrals from health clinics in the surrounding
urban Blantyre area. Furthermore, an unusually dry sea-
son during the recruitment period appeared to play a
role in the low infection rate in the Blantyre population.
However, even with these study modifications, the en-
rollment rate did not increase to the anticipated level.
Ultimately, the study team determined that this enroll-
ment rate was too slow to be feasible, and the study was
stopped due to an insufficient recruitment rate after en-
rolling 20 subjects in part A of the trial (instead of the
anticipated 56 subjects). Correspondingly, the interim
analysis, planned at 20 subjects, became the final
analysis.
Health status
The design of Cryptofaz was based on a pilot study that
did not include information on the health status of po-
tential subjects. Therefore, we were not aware of poten-
tial laboratory abnormalities and occult disease until
screening. The study identified multiple potential sub-
jects who were failing their antiretroviral treatment
(ART) despite being on treatment for months or years.
Related to the low CD4 counts, many subjects were
found to have undiagnosed TB. Also, many potential
subjects were found to be severely hypokalemic because
of their diarrhea and had to receive potassium supple-
mentation prior to enrollment. The study provided care
and close clinical follow-up to these subjects.
High mortality rate
In this resource-limited setting, the team found that
many subjects who fit the inclusion and exclusion cri-
teria were extremely ill and some did not survive the
study period. Hence, the mortality rate (20%) was
slightly higher than initially estimated (15%). With the
addition of LAM TB screening, enrollment was affected
(decreased) as more cases of undiagnosed TB were de-
tected and the mortality rate also decreased.
Study implementation
Lab equipment
The study required acquisition and installation of critical
lab equipment. Most of this equipment had to be pro-
cured from outside Malawi. Therefore, lengthy shipping
times had to be worked into the study timeframe.
Lab testing
Commonly, sites new to clinical research will require
new skill sets. Cryptofaz was a technically complex study
with multiple new laboratory tests and procedures. For
example, examination for reliability of qPCR data was a
new procedure for the study team, and the team
required ongoing review, feedback, and troubleshooting
support from one of the study’s partner institutions.
Randomization timing
The original protocol required randomization to occur
simultaneously with study investigational product, prep-
aration, and dispensation. This required both the
pharmacist and data manager to be available nights and
weekends, times outside of these staff normal working
hours. Therefore, staffing schedules were modified to ac-
commodate any potential out-of-hours study-related
work needed.
Protocol amendments
Cryptofaz was an experimental study that had not been
performed before. Thus, the characteristics of the poten-
tial participants and the enrollment rate were unknown.
For these reasons, the trial required four protocol
amendments to optimize the clinical trial recruitment,
enrollment, and completion.
Data collection forms and data entry
While the clinical team reviewed each data collection
form (DCF) and a data entry plan was developed before
study implementation, ensuring an accurate data entry
process required substantial effort and subsequent clean-
ing up of the data after entry.
Physical space
The study required dedicated space for inpatient treat-
ment as well as for administration of the study. At the
time of study initiation, QECH did not have available
space to dedicate to the study.
Site Internet connectivity
The study relied on an electronic data system whereby
data was to be transferred to the Contract Research
Organization (CRO) in a timely manner for oversight
and monitoring. The local site Internet was unreliable,
and this slowed down training and data entry.
Cultural issues
Blood draws
Cryptofaz required blood draws for the PK studies. In
Malawi, as in many sub-Saharan African countries, col-
lecting blood comes with challenges. This relates to the
conception of blood as a “life force” (thus strength is
drained by losing blood) and to rumors of “blood
suckers” (vampires) who come at night and suck people’s
blood, thereby removing power and fertility from the
person [11].
A few months before the study was to begin, groups of
people in and near Blantyre attacked several persons (in-
cluding health care workers) that were accused of being
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“blood suckers.” During study implementation, these
fears threatened to interfere with the study. During a
regular blood draw of a subject, her guardian became ag-
itated about the number of tubes and accused the clin-
ician of being a “blood sucker.” Others in the ward
joined in with the accusations. Extensive sensitization
and counseling of both ward staff and guardians were re-
quired to improve expectations of study procedures.
Food supplement palatability
The Cryptofaz study required nutritional consistency,
both in terms of content and timing of meals. However,
as nutritional consistency and quality of meals provided
by QECH or guardians could not be ensured, the study
team identified “Plumpy’Nut” [12] and “Plumpy’Soy”
[13] as alternative appropriate food supplements and
found a local source for these products. Some subjects
found the supplement to be unpalatable, and therefore,
the team had to identify ways to make the taste more
acceptable.
Conclusion
The Malawian Cryptofaz study is an example of a suc-
cessful human experimental trial conducted in a low-
income country. Barriers to the conduct of clinical trials
in developing countries have been systematically
reviewed and fall under five unifying themes: lack of fi-
nancial and human capacity, ethical and regulatory sys-
tem obstacles, lack of research environment, operational
barriers, and competing demands [2]. However, few of
the clinical trials listed in the reviews were from Africa
and even fewer from the “least developed” countries as
designated by the Development Assistance Committee
(DAC) [14].
Sub-Saharan African countries face enormous chal-
lenges in conducting high-quality clinical trials. How-
ever, in the case of the Cryptofaz trial in Malawi, the
study team encountered challenges, particularly in the
area of regulatory system and operational barriers, but
were able to overcome most. As a result, the capacity at
the investigational site for conducting clinical trials was
built and/or strengthened. This was particularly true in
relation to the site’s capabilities in clinical services, data
management, pharmacy, study coordination, governance,
and human resources. The challenges, lessons, and rec-
ommendations from Cryptofaz are specific to the study’s
context, but may prove useful to other human experi-
mental trials in sub-Saharan Africa.
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